Fundraising Fox
venBio Partners
Venture capitalSan Francisco · Seed–Series C · 10 people tracked
Also known as VENBIO PARTNERS LLC
Find your way into venBio Partners
Sign up to see every warm intro you have to venBio Partners
- Paths you didn't know you had: your email and LinkedIn already hold routes to the venBio Partners team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
venBio invests in life sciences companies developing novel therapeutics for unmet medical needs. The firm seeks teams building treatments with meaningful impact on patient care and works closely with them on development strategy, including intellectual property, chemistry and manufacturing (CMC), and clinical trial design and regulatory considerations. venBio is mindful of potential acquisition partners from the outset, positioning its companies to meet acquirer requirements. Its team's expertise and hands-on involvement aim to help companies make a larger impact and build lasting relationships with the leaders it backs.
Source: firm website, verified Oct 13, 2026.
Team · 10 people
from the firm's website & public directories
Robert Adelman, a surgeon-turned-investor, brings clinical experience to therapeutics boardrooms and has backed oncology and immunology platforms later acquired by major pharma like Aragon (J&J) and Turning Point (BMS).
Corey Goodman pairs deep neuroscience expertise in neural wiring and axon guidance molecules with hands-on company building—founding eight biotechs including Exelixis and leading Pfizer's Biotherapeutics to align science with pharma acquisition needs.
Richard Gaster combines Harvard-affiliated plastic surgery training and experience as a cancer dad with translational medicine leadership at Pliant, focusing on mechanistically novel aging, CNS, and metabolic disease approaches.
Yvonne Yamanaka combines hands-on technical experience—she helped invent an immunotherapy platform as a graduate student and led its development at EMD/Merck Serono—and built companies from the whiteboard up at Flagship Pioneering.
Jaume Pons personally invented Ajovy (an anti‑CGRP antibody commercialized by Teva), led 13 protein therapeutics into human trials, and co‑founded ALX Oncology, taking it from inception through IPO.
Daniel Teichmann joined venBio in 2019, where he handles fund accounting, fund administration, and compliance, and builds financial models and valuations for current and potential investments. He previously performed valuation services for venture-backed companies at Redwood Valuation Partners and Alvarez & Marsal. He holds a BA in Business Administration with a Finance option from the University of Washington (2016).
David Pezeshki joined venBio in 2016. He previously spent 12 years as Controller/VP of Finance at Alloy Ventures, where he also served as interim CFO for portfolio companies on tax, accounting, and financial matters, and co-founded Redwood Valuation Partners in 2007 to provide valuation services to early-stage startups. Earlier in his career he worked as a Tax Consultant at Ernst & Young; he is a CFA Charterholder and CPA with a BA in Accounting and an MS in Finance from Louisiana State University.
Parthiv Patel is an Analyst at venBio, where he handles scientific and technical diligence of companies developing novel therapeutics. He completed the Roy and Diana Vagelos Program in Life Sciences & Management at the University of Pennsylvania, earning a BA in Biology and a BSc in Economics from the Wharton School with a concentration in Finance. Before joining venBio, he interned at Logos Capital and Matrix Capital, gaining experience investing in public and private biotechnology companies, and previously consulted for the venBio team on investment opportunities.
Founder mafia
2 people who came through venBio Partners went on to found or lead other companies.
What they invest in
from 69 of 90 portfolio companiesBiotech ×64Healthtech ×39Medical Devices ×22Deep Tech ×9AI & Machine Learning ×8Digital Health ×8Advanced Manufacturing ×1Consumer ×1
HQs:United States×51Australia×2Canada×1United Kingdom×1Netherlands×1
Who they back
founder profiles across 27 portfolio companiesFounding team size:solo founder×152 founders×73 founders×44+ founders×1
Where their founders studiedfrom 16 founders with education data
The Johns Hopkins University School of Medicine ×4University of California, Berkeley ×3Harvard University ×2Massachusetts Institute of Technology ×2MIT Sloan School of Management ×2
What their founders studiedfrom 18 founders with field-of-study data
Life Sciences ×12Medicine ×4Engineering ×2Physics ×2
Where their founders worked beforefrom 18 founders with career history
Boston Children's Hospital ×2Gladstone Institutes ×2OrbiMed ×2
Accelerator rootsportfolio companies that came through a program
Investments · 90 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 12024 · 62023 · 32022 · 22021 · 82020 · 62019 · 32018 · 32017 · 42016 · 12015 · 749 dated
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.
BiotechHealthtechMedical DevicesNorthbrook, US
Jeffrey Aronin(Director)inJeffrey M. Dayno, M.D.(President and Chief Executive Officer)inPatrick Morris(Secretary and Treasurer)inRobert Repella(Director and Chief Executive Officer)Darien Parhad(Chief Financial Officer)
Board seatAaron Royston· per SEC Form D
Co-investorsAisling CapitalHBM Healthcare InvestmentsHBM PartnersParagon Biosciences LLCPivotal Life SciencesValor Equity Partners+3 more
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)inDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMichael Amoroso(President, Chief Executive Officer)in
Board seatRobert Adelman· per SEC Form D
Co-investorsage1Agent CapitalAliment CapitalBrace PharmaF-Prime CapitalOCV Partners+6 more
Achieve is a specialty pharmaceutical company developing and commercializing cytisinicline as a treatment for nicotine dependence, aimed at helping people who smoke quit.
BiotechHealthtechVancouver, B.C., US
Anthony Clarke(Executive Officer)Richard Stewart(Co-founder & Director (former President and CEO))Cindy Jacobs(Executive Officer, Director)inJaime Xinos(Executive Officer)inJohn Bencich(Executive Officer, Director)inAndrew D. Goldberg(Chief Executive Officer & Director)in
Co-investorsLifeSci Venture PartnersVivo CapitalFrazier Life Sciences
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Co-investorsForesite CapitalGeneral AtlanticHBM Healthcare InvestmentsHBM PartnersNextech InvestOrbiMed+4 more
AstraZeneca develops and markets pharmaceutical products, vaccines, and biologics across oncology, cardiovascular disease, respiratory and immunology, and rare disease areas, serving patients and healthcare providers globally.
Cambridge, GB
Co-investors+ND Capital
ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.
BiotechHealthtechMedical Devices
Corey Goodman(Chairman)inJason Lettmann(Chief Executive Officer)in
Co-investorsLightstone Venturesage1Foresite CapitalHBM Healthcare InvestmentsHBM PartnersLogos+1 more
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.
BiotechHealthtechMedical DevicesCambridge, US
Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)
Co-investorsAdvent Life SciencesChiesi VenturesColumbus Venture PartnersDroia VenturesForesite CapitalJazzya Investments+6 more
Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations.
BiotechHealthtechCambridge, US
Schuetz Thomas(Executive Officer, Director)inErrik Anderson(Executive Officer, Director)inThomas J. Schuetz(Executive Officer, Director)inVered Bisker-Leib(Executive Officer)inBarry Shin(Chief Financial Officer)inNeil Lerner(Senior Vice President, Chief Accounting Officer)in
Co-investorsAlumni VenturesBioBritF-Prime CapitalForesite CapitalGV (Google Ventures)OrbiMed+3 more
Data I/O provides device programming systems and services for semiconductors including MCUs, UFS, eMMC, NAND flash, and security ICs, along with security provisioning like cryptographic key injection and device identity.
Advanced ManufacturingHardwareSemiconductors
William Wentworth(Chief Executive Officer, President, and Director)in
Immuron is an Australian biopharmaceutical company developing and commercialising targeted polyclonal antibodies aimed at addressing unmet medical needs.
BiotechDigital HealthWellness & Fitness
Steven Lydeamorein
Co-investorsSilver Lake Partners
Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision.
BiotechHealthtechMedical DevicesNew Brunswick, US
Edward Mead JohnsonJames Wood JohnsonRobert Wood Johnson IJoaquin DuatoinJ. Duato(Chief Executive Officer)
Co-investorsAisling CapitalAtlas VentureNaviMed CapitalPortland Seed FundSPRINGROCK VENTURESThe Column Group
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPDeerfield Management CompanyForesite CapitalFrazier Life SciencesGeneral Catalyst+9 more
.png)
Seaport Therapeutics develops therapeutics and medicines.
BiotechMental HealthBoston, US
Daphne Zohar(Founder, CEO & Board Member)inSteven Paul, M.D.(Founder, Board Chair)inMichael Chen, Ph.D.(Co-Founder, Chief Scientific Officer)Michael Chen(Executive Officer)inLana Gladstein(Executive Officer)inAntony Loebel(Executive Officer)in
Co-investorsARCH Venture PartnersForesite CapitalGeneral AtlanticHAWKTAILPureTech HealthSofinnova Ventures+4 more
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
BiotechWaltham, US
John Pallies(Executive Officer)inArlene Morris(Executive Officer, Director)inMichael A. Metzger(Chief Executive Officer)inKeith A. Goldan(Chief Financial Officer)in
BoardDennis Podlesak(Director)inIvor Royston(Director)
Co-investorsAisling CapitalATEM Capital FundAvoro Capital AdvisorsBioBritDelos CapitalEcoR1 Capital+6 more
Tenaya Therapeutics is a biotechnology company focused on discovering and developing therapies for heart disease.
BiotechHealthtechSouth San Francisco, US
Deepak Srivastava, M.D.(Scientific Founder)inEric Olson, Ph.D.(Scientific Founder)Bruce R. Conklin, M.D.(Scientific Founder)inSheng Ding, Ph.D.(Scientific Founder)Saptarsi Haldar, M.D.(Scientific Founder)inEric Hyllengren(Chief Financial Officer)in
Co-investorsGV (Google Ventures)RA CapitalThe Column Group
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in
BoardCorey . Goodman(Director)inJonathan Leff(Director)in
Co-investorsSofinnova VenturesMRL Ventures FundCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture PartnersIaso Ventures+8 more
Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform.
BiotechDigital HealthMedical DevicesRedwood City, US
Emmett Cunningham(Executive Officer, Director)inMark Bachleda(Executive Officer, Director)inRobert Vitti(Executive Officer)inOliver Stauch(Executive Officer)inConrad Wang(Director)in
BoardDan Estes(Director)in
Co-investorsFrazier Life SciencesHealthQuest CapitalRA CapitalvenBio Global Strategic
NorthSea Therapeutics is a clinical-stage biopharmaceutical company developing oral fatty acid-derived therapies for liver and metabolic diseases, including intestinal failure-associated liver disease (IFALD), severe hypertriglyceridemia, and MASH.
BiotechDigital HealthHealthtech
Co-investorsNew Science VenturesYsios CapitalBGVNovo HoldingsBioGeneration VenturesSofinnova Ventures+1 more
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.
BiotechBerkeley, US
Allison J. Hulme(CEO & President)inJohn Kincaid(Chief Scientific Officer)inDavis Ryman(Executive Officer)inMicah Zajic(Executive Officer)inIan Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)
Board seatRichard Gaster· per SEC Form D
Co-investorsCoastCapCTI Life Sciences Fund L.P.Felix JahnFJ LabsLuma GroupSofinnova Ventures+2 more
NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.
BiotechCrestwood, US
Pascal Deschatelets(Executive Officer)inCedric Francois(Executive Officer, Director)in
BoardGerald Chan(Director)Stephanie O'Brien(Director)Alec Machiels(Director)A. Sinclair Dunlop(Director)
Board seatRobert Adelman· per SEC Form D
Co-investorsAvoro Capital AdvisorsEMBL VenturesEpidarex CapitalF-Prime CapitalKeyhorse CapitalSofinnova Ventures+1 more
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)Rahul Kakkar(Director)inGreg Bell(Executive Officer)
Board seatCorey GoodmanRichard Gaster· per SEC Form D
Co-investorsAlpha Wave GlobalBioBritLifeSci Venture PartnersJanus Henderson InvestorsREDMILESamsara BioCapital+2 more
Impel Pharmaceuticals develops therapies for diseases with high unmet medical needs by pairing established drugs with its proprietary upper-nasal drug delivery technology.
BiotechHealthtechMedical DevicesSeattle, US
John D. Hoekman(Executive Officer, Director)in
BoardMichael Hite(Director)Stewart Parker(Director)
Board seatAaron Royston· per SEC Form D · $37.3M raise · filed Dec 2016
Co-investors5AM VenturesB Capital GroupvenBio Global StrategicWestlake Village BioPartners
.jpeg){kind=logo}
Acquired by Lisata Therapeutics alongside a $225 million concurrent private placement.
BiotechSan Francisco, US
Mark Joing(Executive Officer)inChristine Garrett(Executive Officer)inJosh Lehrer(Executive Officer, Director)inEthan Weiss(Executive Officer)inCaitlin Murray(Executive Officer)
BoardJeff Tong(Director)
Board seatAaron Royston· per SEC Form D
Co-investorsAlpha Wave GlobalSofinnova VenturesThird Rock VenturesForbion
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Board seatRobert Adelman· per SEC Form D · $37.8M raise · filed Nov 2016
Co-investorsage1EcoR1 CapitalLAVLifeSci Venture PartnersLilly Asia VenturesNew Enterprise Associates (NEA)+8 more
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)inBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
Board seatAaron Royston· per SEC Form D
Co-investorsLifeSci Venture PartnersSamsara BioCapitalScion Life SciencesSofinnova VenturesTCG CrossoverVersant Ventures+4 more
BiotechSan Francisco, US
Curt Bradshaw(Executive Officer, Director, Promoter)inFrank Muhlenbeck(Mr. Muhlenbeck is a Manager of the Issuer.)
BoardCorey Goodman(Executive Officer, Director, Promoter)inSteven Dowdy(Director)George Rehm(Mr. Rehm is a member of the Board of Managers of the Issuer.)
Board seatRobert Adelman· per SEC Form D · $4M raise · filed Dec 2015
Tallac Therapeutics is a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates (TRAAC candidates) designed to deliver immune-activating agents to tumor microenvironments for oncology indications.
BiotechHealthtechMedical DevicesBurlingame, US
Hong Wan(Executive Officer, Director)in
BoardRan Geng(Director)Michael Carusi(Director)Isaac Cheng(Director)Christine Brennan(Director)
Board seatJaume PonsCorey Goodman· per SEC Form D
Co-investorsLightstone VenturesMRL Ventures FundMatrix Partners ChinavenBio Global Strategic
San Diego, US
Mark S. Forman(Executive Officer)inMatthew Moore(Executive Officer)inJohn Nuss(Executive Officer)inJigar Choksey(Director)Martin Auster(Executive Officer)inChristopher W. Krueger(Executive Officer)
Board seatAaron RoystonRichard Gaster· per SEC Form D
Co-investorsNew Science VenturesThird Point VenturesWellington ManagementSilverArc PrivatevenBio Global Strategic
35Pharma is a biopharmaceutical company developing biologics to treat diseases with high unmet medical need.
BiotechHealthtech
Ilia(CEO)Maureen(CSO)
Co-investorsFrazier Life SciencesJanus Henderson InvestorsVivo Capital
AI & Machine LearningBiotechDigital HealthHealthtech
Co-investorsDecheng CapitalSamsara BioCapitalWestlake Village BioPartnersAccess IndustriesKleiner Perkins
Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureForesite CapitalFrazier Life SciencesGeneral AtlanticLifeSci Venture PartnersScion Life Sciences+2 more
Alexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.
BiotechHealthtechBoston, US
Co-investorsAndera PartnersConnecticut Innovations
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
BiotechHealthtechBoulder, US
Joey Azofeifa(Founder)inLaura Norris(Executive Officer, Director)inTimothy Read(Executive Officer, Director)Eric Martin(Executive Officer)in
BoardAmit Mehta(Director)
Co-investorsATEM Capital FundFifty YearsFundersClubTau VenturesY CombinatorAlamo Angels+9 more
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)inDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesHBM Healthcare InvestmentsHBM PartnersNextech Invest+2 more
Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.
BiotechHealthtechMedical DevicesSan Diego, US
Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)Fred Aslan(Executive Officer, Director)inJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)Peter Flynn(Executive Officer)in
Co-investors5AM VenturesEcoR1 CapitalRA CapitalWellington ManagementvenBio Global Strategic
Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.
BiotechDigital Health
Zaneta Odrowaz(Founder)inTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)Zaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)
Co-investorsEcoR1 CapitalFrazier Life SciencesIllumina VenturesNextech InvestSanofi VenturesVida Ventures+1 more
BiotechSan Francisco, US
Matthew Patterson(Executive Officer, Director)in
BoardJonathan Silverstein(Director)inSteve Squinto(Director)inKush Parmar(Director)inJonathan Leff(Director)Thomas Woiwode(Director)
Co-investorsAsset Management CompanyRA Capital5AM VenturesDeerfield Management CompanyOrbiMedVenrock
Aurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs.
BiotechDigital HealthHealthtechMedical DevicesVictoria, US
Richard M. Glickman(Executive Officer, Director)inStephen W. Zaruby(Executive Officer, Director)Michael Martin(Executive Officer, Director)inDennis Bourgeault(Executive Officer)Mr. Tang(Chief Executive Officer and Chair of the Board)
BoardKurt von Emster(Director)in
Co-investorsLumira VenturesNew Enterprise Associates (NEA)
Axent Biosciences develops stem cell therapies to treat diseases like Parkinson's, using a proprietary cell cultivation platform to enable scalable and cost-effective manufacturing.
BiotechDeep TechHealthtechMedical DevicesNew MaterialsBerkeley, US
David Schaffer(Professor)
Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.
BiotechHealthtech
Praveen Tipirneni(Chief Executive Officer)Liangsu Wang(Chief Scientific Officer)Zhong Liu(Chief Technology Officer)Aaron Pelta(Chief Business Officer)Colm White(Chief Program Officer)
Co-investorsAtlas VentureJanus Henderson InvestorsLAVWellington Management
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalLifeSci Venture PartnersOrbiMedSamsara BioCapitalTCG CrossoverThird Rock Ventures+2 more
Activating the immune system to recognize and destroy tumor cells.
BiotechCambridge, US
Art Krieg(Executive Officer, Director)Barry Labinger(Executive Officer, Director)Chuck Abdalian(Executive Officer)David Mauro(Executive Officer)Karen Brennan(Executive Officer)Charles Yon(Executive Officer)
Co-investorsDecheng CapitalF-Prime CapitalLongitude CapitalSofinnova VenturesNovo Holdings
Entact is a drug discovery company developing treatments for patients.
BiotechDeep TechWatertown, US
Victoria Richon(Executive Officer, Director, Promoter)inRuben Tommasi(Chief Scientific Officer)Michael Gutch(Chief Operating Officer)Alon Lazarus(Director)
BoardAndrew Sinclair(Director)Anna French(Director)in
Co-investorsAbingworthArkin CapitalQiming Venture PartnersvenBio Global Strategic
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
Co-investorsBrandon CapitalKleiner PerkinsNew Enterprise Associates (NEA)Nextech InvestProspect Venture PartnersRho Capital Partners+3 more
HistoWiz provides digital pathology services including precision histology, immunostaining, slide archiving, and AI-powered image analysis for research and clinical laboratories.
AI & Machine LearningBiotechHealthtechMedical DevicesNew York City, US
Ke Cheng(CEO)inLinh Hoang(Chief Executive Officer)inJerry Kuang(Chief Operations Officer)Julie Feldstein(Chief Pathologist)in
Co-investorsAsahi Kasei Corporate Venture CapitalVivo CapitalY CombinatorAvlok CapitalK5 VenturesMicroVentures
Co-investorsDecheng CapitalForesite Capital
Impel Pharmaceuticals develops therapies for patients using its drug delivery technology and expertise with small and large molecules.
BiotechHealthtechMedical Devices
Co-investorsCowles VenturesNorwest Venture Partners
Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data.
AI & Machine LearningBiotechDeep TechChippendale, AU
Tim Craven(CEO)inToby Passioura(Founder)inGlen McIntyre(Founder)Timothy Craven(Founder)
BoardCOREY GOODMAN(Director)inMATT HERSHENSON(Director)in
Co-investorsBEVCCivilization Ventures Management, LlcMRL Ventures FundPlayground GlobalAxial VCvenBio Global Strategic
Lyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology.
BiotechDeep TechHealthtechMedical DevicesBothell, US
Stan Riddell(Executive Officer)Richard Klausner(Executive Officer, Director, Promoter)Stephen Hill(Executive Officer)inHeather Turner(Executive Officer)inRichard Goold(Executive Officer)inMargo Roberts(Executive Officer)
Co-investorsARCH Venture PartnersForesite Capital8VCAxial VC
MindRhythm develops a portable, non-invasive medical device that uses the Headpulse algorithm and AI to triage stroke patients in the prehospital setting, helping paramedics identify Large Vessel Occlusion strokes and route patients to appropriate hospitals faster.
AI & Machine LearningDeep TechDigital HealthMedical Devices
John Keane(Co-Founder & CEO)inPaul Lovoi(Co-Founder & CTO)inWade Smith(Co-Founder & Chair of the Scientific Advisory Board)
Co-investorsDCVC (Data Collective)York IE
Myoventive develops RNA-based medicines to treat genetic heart diseases.
BiotechSouth San Francisco, US
Co-investorsMRL Ventures Fund
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in
BoardDAVID ALLISON(Director)inKLAUS VEITINGER(Director)in
Co-investors5AM VenturesOrbiMedSamsara BioCapitalVivo CapitalRTW Investments L.P.venBio Global Strategic+1 more
NFlection is a biopharmaceutical company developing novel therapeutics.
BiotechMedical DevicesBoston, US
Christopher Powala(Chief Development Officer, Former President & CEO)Mark de Souza(Executive Officer, Director)in
BoardCorey Goodman(Director)Ketan Patel(Director)in
Co-investorsF-Prime CapitalvenBio Global Strategic
Oak Hill Bio develops therapies for patients with rare diseases, supported by experienced life science investors.
BiotechHealthtechMedical Devices
Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.
BiotechHealthtech
Co-investorsBain Capital Life SciencesForesite CapitalGeneral AtlanticKurma PartnersViking Global
Portage is a clinical-stage immuno-oncology company developing novel cancer therapies with a portfolio in drug development.
BiotechHealthtechMedical Devices
Queenly is an online marketplace where users can buy and rent formal wear across iOS, Android, and web platforms.
ConsumerDirect to ConsumerE-commerceMarketplacesSan Francisco, US
Trisha Bantigue(Founder)inKathy Zhou-Patel(Founder)inTrisha Bantigue Tsao(Founder)inMengzhou Zhou(Director)Kathy Zhou(Founder)Dewandra Downs(Software Engineer)
Co-investorsAlumni VenturesAmino CapitalGaingelsInterlace VenturesRebel FundSHAKTI+14 more
-2.png)
__Twitter.png)
Regeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease.
BiotechHealthtechTarrytown, US
Co-investorsRidgeback CapitalSanderling VenturesWireframe Ventures
Teva Pharmaceuticals is a global pharmaceutical company that discovers, develops, and manufactures medicines to treat chronic conditions for patients across 57 markets.
BiotechHealthtechImpact & Social GoodMedical Devices
Co-investorsBlumberg Capital
Verona Pharma develops treatments for chronic lung conditions.
BiotechHealthtechLondon
Jan-Anders Karlsson(Executive Officer, Director)inPeter Spargo(Executive Officer)inPatrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)
Co-investorsAccess BiotechnologyAisling CapitalAndera PartnersForesite CapitalFrazier Life SciencesNew Enterprise Associates (NEA)+4 more
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Founder)inAndrew Bellinger(Executive Officer)Kiran Musunuru(Founder)
BoardJohn Evans(Director)Anthony Philippakis(Director)in
Co-investorsARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalWellington ManagementCasdin Capital+3 more
AI & Machine LearningBiotechHealthtech
Co-investorsAvoro Capital AdvisorsMedicxiTCG CrossoverUniQuest Extension Fund (UEF)JMI Equity
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
14ner OncologyAkero Therapeutics, Inc.Alexo TherapeuticsMenlo TherapeuticsTP TherapeuticsAbdera TherapeuticsAbderatxAblaze PharmaceuticalsAblazepharmaAkoustis TechnologiesAlimera SciencesArtur TherapeuticsAuspex PharmaceuticalsCaldera Therapeutics, Inc.Ceptur TherapeuticsCinncinatusFrequency TherapeuticsGood2Go, IncImmunomedicsINBRACEPhivida HoldingsRyvu TherapeuticsSelecta BiosciencesStargazer PharmaceuticalsSynthorxVentyx BiopharmaceuticalsVertoseViventia Biotech
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 23
17 IPOs · 6 acquisitions · showing 19Harmony BiosciencesNASDAQ: HRMYPrecision BioSciencesNASDAQ: DTILAchieve Life SciencesNASDAQ: ACHVAlumisNASDAQ: ALMSAlumniNYSE: AZNAlx OncologyNASDAQ: ALXOAura BiosciencesNASDAQ: AURACompass TherapeuticsNASDAQ: CMPXData I/ONASDAQ: DAIOImmuronNASDAQ: IMRNJohnson & JohnsonNYSE: JNJParabilis MedicinesNASDAQ: PBLSSeaport TherapeuticsNASDAQ: SPTXSyndax PharmaceuticalsNASDAQ: SNDXTenaya TherapeuticsNASDAQ: TNYAApellis Pharmaceuticalsacq. by BiogenAcelyrinacq. by AlumisSynthorxacq. by SanofiVicebioacq. by Sanofi
Portfolio news
latest coverage across their companies
Syndax Pharmaceuticals · aol.com · Aug 12, 2026
Aura Biosciences · stocktitan.net · Aug 12, 2026
Tenaya Therapeutics · investingnews.com · Aug 5, 2026
Arrakis Therapeutics · biospace.com · Jun 25, 2026
Data I/O · stocktitan.net · Jun 23, 2026
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Alx Oncology | 24.6% | $76.00 | Dec 2020 | $737.2M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has venBio Partners made?
- venBio Partners has 90 tracked investments, 23 of which have exited, including 4 dated in the last 24 months.
- What stage does venBio Partners invest at?
- venBio Partners invests at the Seed, Series A, Series B, Series C stages.
- What sectors does venBio Partners focus on?
- venBio Partners focuses on Biotech, Healthtech, Medical Devices.
- Where is venBio Partners located?
- venBio Partners is headquartered in San Francisco, US.
- Does venBio Partners lead rounds?
- venBio Partners typically participates in rounds rather than leading them.
- Who does venBio Partners co-invest with?
- venBio Partners most often shares deals with Foresite Capital, RA Capital, Sofinnova Ventures, among 120 tracked co-investors.
- What size deals does venBio Partners back?
- Across 17 deals with disclosed amounts, venBio Partners has joined rounds of $12M – $260M (median $62M).
Co-investors · 36
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
Samsara BioCapital is a life-sciences investment firm backing companies developing transformative therapeutics for patients.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Atlas Venture is a biotechnology-focused venture firm that creates and builds breakthrough life science companies, backing entrepreneurs to translate scientific research into new medicines.
Nextech Invest is a Zurich-based investor backing emerging biotechnology companies worldwide, focused on advancing precision medicine and transformative cancer therapies.
Westlake Village BioPartners is a life science venture capital firm based in the Los Angeles area that builds and incubates biotech companies around experienced entrepreneurs.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
General Atlantic is a global investment firm that partners with entrepreneurs and companies to build long-term value through growth equity, credit, energy transition, and infrastructure strategies.
▶24 more co-investors
5AM VenturesThird Rock VenturesKleiner PerkinsCanaan PartnersVersant VenturesAbingworthLilly Asia VenturesGeneral CatalystVenrockPlayground GlobalHouseAccess IndustriesOmega FundsApollo Health VenturesLuma GroupUberEclipse VenturesMorgenthalerCofounders CapitalSeroba Life Sciences4BIO CapitalRunway Growth CapitalKohFoundersMohr Davidow Ventures
Firms observed investing alongside venBio Partners, from public investor directories. Shared companies are the overlap with venBio Partners's recorded portfolio.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is an independent manager of venture capital funds and the listed investment company Quest for Growth, backing innovative companies that use technology as a competitive advantage.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.